Cervical Cancer Series 03 | When Should You Start Cervical Cancer Screening?
Deciding when to begin cervical cancer screening can be surprisingly confusing.
One guideline may recommend starting at age 21, while another says age 25. You may also see World Health Organization guidance referring to age 30.
The recommended interval varies too. Some people are screened every three years, while others are screened every five years. Some receive a Pap test, some receive an HPV test, and others have both at the same time.
So which recommendation should you follow?
There is no single screening schedule that applies to everyone in every country.
The appropriate starting age, test, and interval depend on the guideline used in your country, as well as your previous results and individual risk factors.
Instead of remembering only one age or testing interval, it is important to know:
Which test you received
What your previous result showed
Whether earlier follow-up was recommended
Which guideline your healthcare system follows
Whether you have factors that place you at higher risk
Why Is Cervical Cancer Screening Important?
Almost all cervical cancers are associated with persistent infection with high-risk types of human papillomavirus, or HPV.
Almost everyone who is sexually active will be exposed to HPV at some point. Most infections are cleared naturally by the immune system without causing serious health problems.
However, some high-risk HPV infections persist.
Over time, persistent infection can cause abnormal changes in cervical cells. Many mild changes return to normal, but some may progress to high-grade precancerous lesions.
If a high-grade lesion is not detected and treated, it may eventually develop into invasive cervical cancer.
This progression usually occurs over many years rather than months. That long interval creates an important opportunity to detect and treat abnormal changes before cancer develops.
The purpose of screening is therefore not limited to finding cancer that has already formed.
Depending on the test used, screening can detect high-risk HPV, abnormal cervical cells, or both. Appropriate follow-up and treatment can then prevent many precancerous lesions from progressing to cervical cancer.
Screening Is Different From Evaluating Symptoms
Routine cervical cancer screening is intended for people who do not have symptoms.
If you develop symptoms that could be related to the cervix or another part of the reproductive system, you should not wait until your next scheduled screening appointment.
Symptoms that should be evaluated include:
Bleeding after sex
Bleeding between periods
Periods that are heavier or last longer than usual
Bleeding after menopause
Vaginal discharge that is unusual for you
Foul-smelling vaginal discharge
Persistent pelvic pain
Pain during sex
These symptoms do not necessarily mean that you have cervical cancer. Infections, cervical polyps, hormonal changes, and other gynecologic conditions can cause similar symptoms.
However, a medical evaluation is still needed to determine the cause.
Screening looks for HPV infection or precancerous changes in someone without symptoms. Diagnostic evaluation investigates an existing symptom or abnormal finding.
Even if your most recent screening result was normal, new bleeding, persistent pain, or unusual discharge should be evaluated promptly.
What Is the Difference Between a Pap Test and an HPV Test?
Pap and HPV tests are both used in cervical cancer screening, but they look for different things.
Pap Test
A Pap test, also called cervical cytology or a Pap smear, looks for abnormal changes in cervical cells.
A healthcare professional uses a small brush or similar instrument to collect cells from the cervix. The sample is sent to a laboratory, where the cells are examined for changes that may indicate a precancerous lesion or cancer.
A Pap test does not directly test for HPV. It looks for cellular changes that may have developed because of HPV infection or another process.
An abnormal Pap result does not automatically mean that you have cervical cancer.
Temporary HPV infection, mild cell changes that may return to normal, and reactive changes associated with inflammation or infection can affect the result.
The next step depends on several factors, including:
The type and severity of the abnormality
Your age
Your HPV test result
Your previous screening history
You may be advised to repeat the test after a certain period. In other cases, colposcopy or biopsy may be recommended to examine the cervical tissue more closely.
HPV Test
An HPV test looks for high-risk HPV types associated with cervical cancer.
Rather than examining cervical cells for abnormal changes, it identifies the virus that can cause those changes.
A positive high-risk HPV result does not mean that you have cervical cancer.
HPV infection is common, and many infections disappear without treatment. A positive result alone cannot diagnose cancer or prove that cancer will eventually develop.
Persistent high-risk HPV infection, however, requires appropriate follow-up.
Detection of HPV 16 or HPV 18 may lead to colposcopy or another evaluation even when cytology is normal, depending on the guideline and the complete test result. These two types are particularly strongly associated with cervical cancer.
A negative high-risk HPV result means that the test did not detect one of the high-risk types it was designed to identify at that time.
Because HPV testing is highly effective at identifying people at risk of cervical lesions, some guidelines allow a longer interval after a negative result.
Cotesting
A Pap test and an HPV test can also be performed together. This is called cotesting.
Cotesting provides two kinds of information:
Whether abnormal cervical cells are present
Whether high-risk HPV is present
Not everyone needs both tests.
Depending on your age, the tests available, and the guideline used by your healthcare system, routine screening may involve:
A Pap test alone
Primary HPV testing
Cotesting with both a Pap test and an HPV test
Because the recommended interval depends on the test used, check your result report instead of remembering only that you were “screened.”
At What Age Should Cervical Cancer Screening Begin?
There is no single starting age used by every medical organization or country.
In the United States, major guidelines currently recommend beginning routine screening at either age 21 or age 25, depending on the organization.
The World Health Organization recommends that population-based screening programs for the general population begin at age 30 with a high-performance test.
These differences do not mean that one guideline is safe and another is unsafe.
Each organization considers:
The screening test being used
The benefits of detecting precancerous changes
The risk of unnecessary procedures
Cervical cancer rates in the population
Access to testing and follow-up care
The structure of the healthcare system
The appropriate starting age therefore depends on the guideline that applies where you receive care.
Current U.S. Screening Recommendations
Several organizations publish cervical cancer screening recommendations in the United States, and they do not all use the same starting age.
As of August 2026, the current final recommendation from the U.S. Preventive Services Task Force, or USPSTF, remains its 2018 recommendation.
For average-risk people with a cervix, the USPSTF recommends beginning screening at age 21.
From ages 21 through 29, the recommended approach is:
Pap testing alone every three years
From ages 30 through 65, the recommended options are:
Pap testing alone every three years
Primary high-risk HPV testing every five years
Cotesting with a Pap test and high-risk HPV test every five years
The USPSTF released a draft update in December 2024, but a draft is not a final recommendation.
The draft continues to recommend Pap testing every three years from ages 21 through 29. Beginning at age 30, it identifies primary HPV screening every five years as the preferred approach and includes both clinician-collected and self-collected samples.
Until an updated final recommendation is issued, the 2018 statement remains the official final USPSTF guidance.
The American Cancer Society, or ACS, uses a different starting age.
The ACS recommends that average-risk people with a cervix begin screening at age 25. Its preferred method is primary HPV testing using a cervical sample collected by a healthcare professional every five years.
Current ACS screening options include:
Clinician-collected primary HPV testing every five years
Approved self-collected HPV testing every three years
Cotesting every five years
Pap testing alone every three years when HPV testing is not available
The ACS updated its guidance in 2025 to include approved self-collected vaginal samples as an acceptable option for primary HPV screening.
A healthcare professional must still order the test. Depending on the approved test and screening program, the vaginal sample may be collected privately in a healthcare setting or at home.
A self-collected vaginal sample is not the same as a cervical sample collected by a healthcare professional.
Clinician-collected cervical samples remain preferred because they may allow additional testing to be performed from the same sample if an abnormality is found.
The different USPSTF and ACS starting ages can understandably cause confusion.
If you receive care in the United States, ask which guideline your healthcare organization follows and which screening methods are available. Do not select a starting age or testing interval solely by comparing isolated recommendations online.
Why Does the WHO Recommend Starting at Age 30?
The World Health Organization recommends that population-based screening programs for the general population begin at age 30 and use a high-performance test every five to ten years.
For women living with HIV, the WHO recommends beginning at age 25 and screening every three to five years. HIV can increase the likelihood that high-risk HPV infection will persist and progress.
The WHO recommendation is primarily a population-level strategy for countries developing or improving national cervical cancer prevention programs.
It is not intended to replace every country’s established clinical screening schedule.
Countries adapt screening programs according to their:
Cervical cancer burden
Available medical resources
Laboratory capacity
Access to HPV testing
Ability to provide follow-up and treatment
Existing national screening infrastructure
If your country has an established program that begins before age 30, the WHO starting age is not a reason to delay screening.
Follow the official guidance used in the country and healthcare system where you receive care.
Why Do Screening Guidelines Use Different Starting Ages?
Screening guidelines must balance potential benefits with possible harms.
HPV infections are especially common in adolescents and young adults after sexual activity begins. Most of these infections are temporary and clear naturally.
If HPV testing begins too early, it can detect many infections that would never cause a serious cervical lesion.
A positive result may cause anxiety and lead to repeat testing, colposcopy, biopsy, or other procedures that ultimately provide little benefit.
High-grade cervical lesions require proper evaluation and treatment. At the same time, medical organizations try to avoid overtreating mild abnormalities that are likely to return to normal.
Procedures such as loop electrosurgical excision, commonly called LEEP, and cone biopsy remove tissue from the cervix. These procedures may increase the risk of preterm birth in a future pregnancy, particularly when a larger or deeper amount of cervical tissue is removed.
This does not mean that necessary treatment should be avoided. It means that the benefits of treatment must be weighed against the risks of unnecessary intervention.
Healthcare systems also vary substantially among countries.
Some rely primarily on Pap testing and begin screening earlier. Others use primary HPV testing, begin later, and allow longer intervals between negative tests.
These are different evidence-based strategies designed to achieve the same goal: preventing cervical cancer while minimizing unnecessary testing and treatment.
How Often Should You Be Screened?
More frequent screening is not always better.
Testing more often than recommended can detect temporary HPV infections or minor cell changes that would have resolved naturally. This may lead to unnecessary worry, repeated testing, and procedures.
Waiting too long beyond the recommended interval, however, can allow a precancerous lesion to remain undetected.
The goal is to follow the interval appropriate for the test you received.
For average-risk people with normal or negative results, common intervals include:
Pap testing alone every three years
Clinician-collected primary HPV testing every five years
Cotesting every five years
Approved self-collected HPV testing every three years under current ACS guidance
These are routine screening intervals. They are not follow-up schedules for someone who has already received an abnormal result.
If your Pap or HPV result was abnormal, you may need:
Repeat testing after one year
Colposcopy
Biopsy
Another individualized follow-up plan
Even if routine Pap testing is usually recommended every three years, you should not wait three years when your healthcare professional has advised earlier follow-up.
The plan based on your individual result always takes priority over a general screening schedule.
Do You Still Need Screening After HPV Vaccination?
Yes. HPV vaccination does not replace routine cervical cancer screening.
Vaccination is highly effective at preventing infection with the major high-risk HPV types responsible for most cervical cancers. Protection is greatest when the recommended vaccine series is completed before exposure to HPV.
However, currently available vaccines do not protect against every cancer-causing HPV type.
Cervical cell changes can still develop because of a high-risk HPV type not included in the vaccine.
The vaccine also does not treat an infection that was already present before vaccination. If you had already been exposed to a particular HPV type, vaccination will not eliminate that infection, although it may protect you against other types included in the vaccine.
Vaccination and screening therefore serve different but complementary purposes.
Vaccination helps prevent infection with important high-risk HPV types. Screening checks whether high-risk HPV or abnormal cervical cells are present.
Do not stop screening or extend the interval simply because you have been vaccinated. Follow the schedule that applies to your age, previous results, risk factors, and healthcare system.
Can Screening Stop After Age 65?
Some guidelines allow routine screening to stop after age 65 when specific conditions are met.
Turning 65 does not automatically mean that screening is no longer necessary.
Before stopping, a healthcare professional should confirm that you have had adequate previous screening and that your recent results were normal or negative.
Under U.S. guidance, adequate prior screening has traditionally been defined as:
Three consecutive negative Pap tests within the previous ten years, or
Two consecutive negative HPV-based tests within the previous ten years
The most recent test must also have been completed within the interval specified by the applicable guideline.
Exact criteria can vary. If your previous records are unavailable or you have not been screened regularly, you may still need screening after age 65.
A routine stopping rule may also be inappropriate if you have:
A history of high-grade cervical precancer
Previous cervical cancer
HIV
A significantly weakened immune system
Another condition that increases your risk
If you were treated for CIN2, CIN3, or adenocarcinoma in situ, long-term surveillance is generally recommended for at least 25 years after treatment. This may continue beyond age 65.
Do not stop screening based on age alone. Review your previous test dates, results, and treatment history with a healthcare professional first.
Do You Need Screening After a Hysterectomy?
A hysterectomy does not automatically eliminate the need for screening or surveillance.
The first question is whether your cervix was removed.
A total hysterectomy removes both the uterus and cervix. A supracervical or subtotal hysterectomy removes the uterus but leaves the cervix in place.
If your cervix remains, routine cervical cancer screening may still be necessary.
If both the uterus and cervix were removed for a noncancerous condition and you have no history of a high-grade cervical lesion or cervical cancer, routine screening may no longer be needed.
However, if you previously had CIN2, CIN3, adenocarcinoma in situ, or cervical cancer, you may still require long-term follow-up after the cervix has been removed.
This is not routine cervical cancer screening. It is post-treatment surveillance, which may include testing of the vaginal cuff depending on your history and clinical guidance.
Simply saying “I had a hysterectomy” does not reveal whether the cervix was removed or why the operation was performed.
To determine whether you still need screening or surveillance, confirm:
Whether your cervix was removed
Why the surgery was performed
Whether you have ever had a high-grade cervical lesion
Whether you have ever had cervical cancer
If you are uncertain, ask a healthcare professional to review your surgical and pathology records.
When Does a Routine Screening Schedule Not Apply?
Most screening schedules available online are intended for people at average risk.
You may need an individualized screening or surveillance plan if:
A previous Pap or HPV test was abnormal
You have been treated for adenocarcinoma in situ
You have had cervical cancer
You are living with HIV
Your immune system is weakened by an organ transplant, immunosuppressive medication, or another condition
You were exposed to diethylstilbestrol, or DES, before birth
You have had a hysterectomy
Your previous screening records are unavailable
Follow-up after an abnormal result may occur much sooner than routine screening.
If you have been treated for a high-grade lesion or cervical cancer, follow the long-term surveillance plan recommended by your healthcare team rather than the general schedule for average-risk people.
People living with HIV or those with significant immune suppression may need to begin screening earlier or receive it more frequently because HPV infection is more likely to persist and progress.
If any of these circumstances apply to you, do not rely on a general age chart alone to determine when your next test is due.
How to Find the Right Screening Schedule for You
If you do not remember when you were last screened or are unsure when your next test is due, check the following information.
First, identify the official screening guideline used in the country and healthcare system where you receive care.
Then confirm:
Your age
The date of your most recent screening
The type of test you received
The result of that test
Whether additional testing was recommended
Whether you have had an abnormal result in the past
Whether you have been treated for a high-grade cervical lesion
Whether you have any condition that weakens your immune system
Whether your cervix remains after a hysterectomy
Your report may describe the test as cervical cytology, a Pap test, a high-risk HPV test, or Pap and HPV cotesting. Each may have a different recommended interval.
Do not look only at whether the result was described as normal or negative. Check whether repeat testing, colposcopy, or another follow-up procedure was recommended.
Continue tracking your screening schedule even if you have received the HPV vaccine.
After each screening, keep a record of:
The test date
The type of test
The result
Any recommended additional testing
The date your next test is due
Keeping your results can be especially helpful if you move or change healthcare providers.
If you have not been screened for several years or cannot locate your previous records, contact a healthcare professional instead of estimating your next screening date yourself.
Key Takeaways
Cervical cancer screening is performed before symptoms develop. Depending on the method used, it can identify high-risk HPV, abnormal cervical cells, or both.
A Pap test looks for changes in cervical cells. An HPV test looks for high-risk HPV types that can cause those changes.
Screening recommendations do not begin at the same age everywhere.
In the United States, the current final USPSTF recommendation begins Pap screening at age 21. The American Cancer Society recommends beginning at age 25 and prefers primary HPV testing.
The WHO recommends that population-based programs for the general population begin screening at age 30 with a high-performance test. This is a global public health strategy and does not replace an established national screening program.
For average-risk people with normal or negative results, common intervals include Pap testing every three years, clinician-collected primary HPV testing every five years, and cotesting every five years. Under current ACS guidance, approved self-collected HPV testing is generally repeated every three years after a negative result.
These routine intervals do not apply after an abnormal result. An individualized follow-up schedule always takes priority.
HPV vaccination does not replace screening. The vaccine does not cover every cancer-causing HPV type and cannot treat an infection that was already present.
Turning 65 or having a hysterectomy does not automatically mean that screening or surveillance can stop.
Previous results, the type of surgery performed, whether the cervix remains, and any history of high-grade cervical precancer or cancer must all be considered.
People treated for CIN2, CIN3, or adenocarcinoma in situ may need surveillance for at least 25 years after treatment, even if that period extends beyond age 65.
If you develop bleeding after sex, bleeding between periods, bleeding after menopause, unusual vaginal discharge, or persistent pelvic pain, do not wait for your next routine screening appointment.
The most important question is not whether everyone should begin screening at exactly the same age or receive the same test.
What matters is following the schedule appropriate for your country, age, screening method, previous results, and individual risk factors.
Cervical cancer is one of the cancers that can often be prevented by finding and treating abnormal changes before they become invasive.
Do not wait for symptoms to appear. Continue screening according to the schedule that is appropriate for you.
References
U.S. Preventive Services Task Force. Cervical Cancer: Screening—Final Recommendation Statement. August 21, 2018.
https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screeningU.S. Preventive Services Task Force. Draft Recommendation: Cervical Cancer Screening. December 10, 2024.
https://www.uspreventiveservicestaskforce.org/uspstf/draft-recommendation/cervical-cancer-screening-adults-adolescentsAmerican Cancer Society. The American Cancer Society Guidelines for the Prevention and Early Detection of Cervical Cancer. Updated December 4, 2025.
https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-staging/cervical-cancer-screening-guidelines.htmlWorld Health Organization. Cervical Cancer. Updated July 3, 2026.
https://www.who.int/news-room/fact-sheets/detail/cervical-cancerNational Cancer Institute. Cervical Cancer Screening. Updated February 13, 2025.
https://www.cancer.gov/types/cervical/screeningNational Cancer Institute. HPV and Pap Test Results: Next Steps After an Abnormal Cervical Cancer Screening Test. Updated June 6, 2024.
https://www.cancer.gov/types/cervical/screening/abnormal-hpv-pap-test-resultsCenters for Disease Control and Prevention. Reducing Risk for Cervical Cancer. Updated December 11, 2024.
https://www.cdc.gov/cervical-cancer/prevention/index.htmlPerkins RB, Guido RS, Castle PE, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. 2020;24(2):102–131.
https://doi.org/10.1097/LGT.0000000000000525
Comments
Post a Comment